Tonix Pharmaceuticals and Southern Research Announce Expansion of COVID-19 Vaccine CollaborationGlobeNewsWire • 06/18/20
Tonix Pharmaceuticals Announces that Results from Preclinical Studies of TNX-1700 Will be Presented in a Poster at the AACR Virtual Annual Meeting 2020GlobeNewsWire • 06/17/20
Tonix Pharmaceuticals Announces Acquisition of Non-Addictive Migraine and Pain Treatment Programs from Trigemina and Assumption of LicenseGlobeNewsWire • 06/11/20
Tonix Pharmaceuticals Announces Appointment of Richard H. Bagger to Board of DirectorsGlobeNewsWire • 06/10/20
Tonix Pharmaceuticals Announces FUJIFILM Diosynth Biotechnologies to be Manufacturing Partner for COVID-19 Vaccine Candidate TNX-1800GlobeNewsWire • 06/01/20
Tonix Pharmaceuticals Posted Results from Pharmacokinetic Analyses of TNX-102 SL and TNX-601 CR in Advance of Virtual Poster Presentations at the American Society of Clinical PsychopharmacologyGlobeNewsWire • 05/21/20
Tonix Pharmaceuticals Announces Appointment of Herbert Harris, M.D., Ph.D., as Executive Vice President, Translational MedicineGlobeNewsWire • 05/19/20
Tonix Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational HighlightsGlobeNewsWire • 05/12/20
Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 RELIEF Study of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for Management of FibromyalgiaGlobeNewsWire • 04/24/20
Tonix Pharmaceuticals to Deliver Virtual Presentation and Participate in Panel Discussion for Planet MicroCap Showcase Virtual Investor Conference 2020GlobeNewsWire • 04/20/20
Tonix Pharmaceuticals Holding Corp. Closes $16,005,000 Common Stock Registered Direct OfferingGlobeNewsWire • 03/03/20
Tonix Pharmaceuticals, Inc. Prices $16,005,000 Common Stock Offering Priced At-The-MarketGlobeNewsWire • 02/28/20
Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 RECOVERY Study of Tonmya® (TNX-102 SL) in PTSDGlobeNewsWire • 02/05/20
Tonix Pharmaceuticals Moves Ahead, And Other News: The Good, Bad, And Ugly Of BiopharmaSeeking Alpha • 01/30/20
Tonix Pharmaceuticals Presented Results from a Preclinical Study of TNX-801, a Potential Vaccine to Prevent Smallpox and Monkeypox, in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats ConferenceGlobeNewsWire • 01/29/20
Tonix Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SLGlobeNewsWire • 01/24/20
Tonix Pharmaceuticals Announces Plan to Develop TNX-601 CR Tablets for Once-Daily Treatment of Major Depressive Disorder, in Addition to PTSD, After Successful Completion of Phase 1 Pharmacokinetic StudyGlobeNewsWire • 12/16/19
Tonix Pharmaceuticals Announces New European Patent for the Composition and Formulation of TNX-102 SLGlobeNewsWire • 12/11/19
Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study of TNX-102 SL for the Management of FibromyalgiaGlobeNewsWire • 12/10/19
Tonix Pharmaceuticals Announces Receipt of FDA Official Minutes from Breakthrough Therapy Type B Clinical Guidance Meeting for Tonmya® as a Potential New Treatment for PTSDGlobeNewsWire • 11/26/19
Tonix Pharmaceuticals Announces Initiation of the Phase 3 RELIEF Study of TNX-102 SL for the Management of FibromyalgiaGlobeNewsWire • 11/21/19
Tonix Pharmaceuticals Completes Pre-IND Meeting with FDA for TNX-102 SL as a Clinical Candidate for Alcohol Use DisorderGlobeNewsWire • 11/20/19